fingolimod has been researched along with Lymphopenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, C; Chollate, S; Guckian, KM; Hahm, K; Hetu, G; Jin, P; Kumaravel, G; Lee, WC; Lin, EY; Luo, Y; Lynch, KR; Ma, B; Macdonald, TL; Rohde, E; Rossomando, A; Scannevin, R; Scott, D; Wang, J; Yang, C | 1 |
| Bernier, SG; Deng, H; Doyle, E; Evindar, G; Lorusso, J; Morgan, BA; Westlin, WF | 1 |
2 other study(ies) available for fingolimod and Lymphopenia
| Article | Year |
|---|---|
Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.
Topics: Administration, Oral; Animals; Crystallography, X-Ray; Immunosuppressive Agents; Lymphopenia; Mice; Models, Molecular; Multiple Sclerosis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Prodrugs; Receptors, Lysosphingolipid; Structure-Activity Relationship; Tetrahydronaphthalenes | 2010 |
Exploring amino acids derivatives as potent, selective, and direct agonists of sphingosine-1-phosphate receptor subtype-1.
Topics: Administration, Oral; Amino Acids; Animals; Inhibitory Concentration 50; Lymphopenia; Mice; Molecular Structure; Protein Binding; Receptors, Lysosphingolipid | 2013 |